For the quarter ending 2026-03-31, DNA made $19,474K in revenue. -$83,244K in net income. Net profit margin of -427.46%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 19,474 | 33,396 | 38,837 | 49,604 |
| Cost of revenue-Service | - | 7,990* | - | - |
| Cost of biosecurity revenue-Biosecurity | - | - | 8,177 | - |
| Cost of revenue-Product | - | 0* | - | - |
| Cost of biosecurity revenue-Other Revenue | - | - | 4,625 | - |
| Cost of revenue-Product And Service Other | - | -689* | - | 5,380 |
| Cost of other revenue | 3,098 | - | - | - |
| Research and development | 49,920 | 50,127 | 69,353 | 53,370 |
| Impairment of lease assets | - | 0* | - | - |
| Goodwill impairment | - | 0* | 0 | 0 |
| General and administrative | 37,830 | 46,014 | 44,954 | 43,279 |
| Cost of biosecurity revenue-Biosecurity Segment | - | - | - | 9,442 |
| Restructuring charges | 0 | 706 | 1,745 | 3,674 |
| Total operating expenses | 90,848 | 104,148 | 128,854 | 115,145 |
| Loss from operations | -71,374 | -70,752 | -90,017 | -65,541 |
| Interest income | - | 4,710* | - | - |
| Interest expense | - | 0* | - | - |
| Loss on equity method investments | - | 0* | - | - |
| Interest income, net | 3,596 | - | 5,742 | 6,083 |
| Loss on investments | -1,214 | -16,173 | 3,684 | -229 |
| Loss on deconsolidation of subsidiary | - | - | 0 | - |
| Loss on deconsolidation of subsidiaries | - | 0* | - | - |
| Change in fair value of warrant liabilities | - | 0* | 0 | 0 |
| Other expense, net | -7,147 | 821 | -163 | -896 |
| Total other expense | -4,765 | -10,642 | 9,263 | 4,958 |
| Loss from continuing operations before income taxes | -76,139 | -81,394 | -80,754 | -60,583 |
| Income tax (benefit) expense | -80 | -643 | 1 | -283 |
| Net loss from continuing operations | -76,059 | - | - | - |
| Net loss from discontinued operations, net of tax | -6,528 | - | - | - |
| Net loss | -82,587 | -80,854* | -80,755 | - |
| Foreign currency translation adjustment | -579 | 883* | 27 | - |
| Net loss | - | - | - | -60,300 |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | - | 0* | 0 | - |
| Foreign currency translation adjustment | - | - | - | 2,586 |
| Unrealized gain on available-for-sale securities | - | -31* | - | - |
| Debt securities, available-for-sale, unrealized gain (loss) | - | - | - | -83 |
| Unrealized gains (loss) on available-for-sale securities | -78 | - | 316 | - |
| Total other comprehensive income (loss) | - | 914* | - | - |
| Total other comprehensive (loss) income | -657 | - | 343 | 2,503 |
| Comprehensive loss | -83,244 | -79,940 | -80,412 | -57,797 |
| Basic EPS | -1.39 | -1.4 | -1.45 | -1.1 |
| Diluted EPS | - | -1.4 | -1.45 | -1.1 |
| Basic Average Shares | 59,563,454 | 57,096,385 | 55,633,718 | 54,858,982 |
| Diluted Average Shares | - | 57,096,385 | 55,633,718 | 54,858,982 |
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)